Phenotype Image Detail

Image

Caption

Drug treatment of mammary carcinomas in Eef1a1^{tm1(Kras*)Arge}/Eef1a1⁺ Wap^tm1(cre)Arge/Wap⁺ mice. (A) Examples of gross anatomical examination of tumors that developed in mice carrying an activated Kras* oncogenic transgene (Eef1a1^{tm1(Kras*)Arge}/Eef1a1⁺ Wap^tm1(cre)Arge/Wap⁺) after 3 weeks of treatment either with vehicle (V) or with picropodophyllin (P). (B) Histological examination of the tumors shows that in comparison with the controls (V), the PPP-treated tumors are dramatically smaller (P; dotted circles). (C) Compared with vehicle injections (V), administration of PPP for 3 days (P) increases ~9-fold the level of apoptosis detected in the pale component, as assayed by activated caspase 3 immunohistochemistry brown staining. (D) Comparison of the effects on the components of Kras*-induced carcinomas between PPP administration (P) and vehicle injections (V) for 3 weeks. The PPP treatment diminishes the size of pale cell tumors (dotted circles) and results in extensive keratinization and vacuolation (Inset) of the squamous component. The sarcomatous component remaining after treatment might be overestimated, because it exhibits variable degrees of degenerate changes that are difficult to quantitate, including replacement fibrosis (increased matrix and collagen deposition and proliferation of Fosl1-negative myofibroblasts). (Scale bar, 0.5 cm.) (Magnification: C, D, 400X; C Inset, D Inset, 100X.)

Copyright

This image is from Klinakis A, Proc Natl Acad Sci U S A 2009 Feb 17;106(7):2359-64. Copyright 2009 National Academy of Sciences, U.S.A. J:146290

Associated Alleles

Symbol	Name
Eef1a1^tm1(Kras*)Arge	eukaryotic translation elongation factor 1 alpha 1; targeted mutation 1, Argiris Efstratiadis
Wap^tm1(cre)Arge	whey acidic protein; targeted mutation 1, Argiris Efstratiadis

Associated Genotypes

Allelic Composition	Genetic Background
Eef1a1^tm1(Kras*)Arge/Eef1a1^+ Wap^tm1(cre)Arge/Wap^+	involves: 129S1/Sv